About this podcast:
This podcast, recorded at the 2025 Immuno-Oncology 360º (IO360º) Summit, explores the clinical and market implications of emerging data on bispecific antibodies targeting PD-1 and VEGF and their potential to disrupt existing immunotherapy paradigms.More specifically:
- Assessing the potential of this therapeutic approach to challenge established treatments like pembrolizumab by targeting both PD-1 and VEGF
- Insights into how these developments could influence industry trends and investor sentiment
- Forward-looking forecasts on market share and commercial positioning for PD-1/PD-L1 and VEGF-targeting therapies
For more information, go to IO360summit.com.
Speakers
Roy Baynes, MD, PhD
EVP & CMO
Eikon Therapeutics
Asthika Goonewardene, MBA
Managing Director, Senior Biotech Analyst
Truist Securities
This content was created by The Conference Forum staff. The Fierce editorial team did not contribute to this work.